pharmachologic effect

Antihypertensive agent. It is a non-peptidic blocker of angiotensin II receptors. It has high selectivity and affinity for AT1 receptors (with the participation of which the main effects of angiotensin II are realized). Blocking these receptors, losartan prevents and eliminates the vasoconstrictive effect of angiotensin II, its stimulating effect on the secretion of aldosterone by the adrenal glands and some other effects of angiotensin II. Characterized by a prolonged action (24 hours or more), which is due to the formation of its active metabolite.

Indications

Arterial hypertension.

Reducing the risk of associated cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy, manifested by a decrease in the total incidence of cardiovascular mortality, stroke and myocardial infarction.

Protection of the kidneys in patients with type 2 diabetes mellitus with proteinuria is a slowdown in the progression of renal failure, manifested by a decrease in the frequency of hypercreatininemia, the incidence of end-stage renal disease, requiring hemodialysis or renal transplantation, mortality rates, and a decrease in proteinuria.

Chronic heart failure (as part of combination therapy, with intolerance or ineffective therapy with ACE inhibitors).